Search results for B7

Anti-Human CD86/B7-2 Antibody (2331/FUN-1) (HW776307), abinScience, HW776307

Research Grade Anti-B7-H4 & CD3 Bispecific Antibody (Gen1047) (HV721106), abinScience, HV721106

Anti-Human CD274/PD-L1/B7-H1 Antibody (SP263) (HV974083), abinScience, HV974083

Omburtamab Biosimilar – Anti-CD276, B7-H3, B7RP-2 mAb – Research Grade, ProteoGenix, PX-TA1532

Description of Omburtamab Biosimilar - Anti-CD276, B7-H3, B7RP-2 mAb - Research Grade Introduction to Omburtamab Biosimilar – Anti-CD276, B7-H3, B7RP-2 mAb Omburtamab Biosimilar, also known as Anti-CD276, B7-H3, B7RP-2 mAb, is a monoclonal antibody that has been developed as a potential therapeutic agent for various types of cancer. This biosimilar is designed to target the CD276 protein, also known as B7-H3 or B7RP-2, which is overexpressed in many types of cancer cells. In this article, we will explore the structure, activity, and potential applications of Omburtamab Biosimilar. Structure of Omburtamab Biosimilar Omburtamab Biosimilar is a recombinant humanized monoclonal antibody that has been engineered to specifically target the CD276 protein. It is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and a half-life of about 21 days. The binding site of Omburtamab Biosimilar is located on the Fc region of the antibody, which allows for interaction with immune cells and activation of immune responses. The variable regions of the antibody, also known as the antigen-binding sites, are responsible for binding to the CD276 protein on the surface of cancer cells. Activity of Omburtamab Biosimilar The main activity of Omburtamab Biosimilar is its ability to bind to the CD276 protein on the surface of cancer cells. This binding triggers a series of immune responses, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These responses result in the destruction of cancer cells and inhibition of tumor growth. In addition, Omburtamab Biosimilar has been shown to have a direct anti-tumor effect by inducing apoptosis, or programmed cell death, in cancer cells. This is achieved by blocking the signaling pathways involved in cancer cell survival and proliferation. Applications of Omburtamab Biosimilar Omburtamab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer, including neuroblastoma, melanoma, and lung cancer. It has also been investigated for its potential to treat other diseases, such as autoimmune disorders and infectious diseases. In neuroblastoma, Omburtamab Biosimilar has shown to be effective in targeting and killing cancer cells, while sparing healthy cells. This makes it a potential treatment option for this aggressive form of childhood cancer. In melanoma, Omburtamab Biosimilar has been shown to enhance the anti-tumor effects of other therapies, such as chemotherapy and immune checkpoint inhibitors. This makes it a promising candidate for combination therapy in the treatment of this deadly form of skin cancer. In lung cancer, Omburtamab Biosimilar has shown to be effective in targeting cancer cells that have become resistant to chemotherapy. It has also been shown to enhance the activity of other targeted therapies, such as EGFR inhibitors. Conclusion In summary, Omburtamab Biosimilar – Anti-CD276, B7-H3, B7RP-2 mAb – Research Grade is a promising monoclonal antibody that has been designed to target the CD276 protein, which is overexpressed in many types of cancer cells. Its unique structure and activity make it a potential treatment option for various types of cancer, including neuroblastoma, melanoma, and lung cancer. Omburtamab Biosimilar is currently being evaluated in clinical trials and has the potential to improve the outcomes of cancer patients.

ABflo® 594 Rabbit anti-Human CD275/B7-H2/ICOSL mAb, ABclonal, A24718

ABflo® 450 Rabbit anti-Human/Mouse CD276/B7-H3 mAb, ABclonal, A26357

ABflo® 700 Rabbit anti-Human/Mouse CD276/B7-H3 mAb, ABclonal, A26358

Human T-lymphocyte activation antigen CD80 / B7-1 (CD80) ELISA Kit, Abbexa, abx250225

Human T-lymphocyte activation antigen CD80 / B7-1 (CD80) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Human T-lymphocyte activation antigen CD80 / B7-1 (CD80) concentrations in tissue homogenates, cell lysates and other biological fluids.

Mouse T-lymphocyte activation antigen CD80 / B7-1 (CD80) ELISA Kit, Abbexa, abx050037

Mouse T-lymphocyte activation antigen CD80 / B7-1 (CD80) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Mouse T-lymphocyte activation antigen CD80 / B7-1 (CD80) concentrations in tissue lysates, culture media serum and other biological fluids.

Human T-Lymphocyte Activation Antigen CD86 / B7-2 (CD86) ELISA Kit, Abbexa, abx152146

Human T-Lymphocyte Activation Antigen CD86 / B7-2 (CD86) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Human T-Lymphocyte Activation Antigen CD86 / B7-2 (CD86) concentrations in serum, plasma, tissue homogenates, cell lysates and other biological fluids. This assay has high sensitivity and excellent specificity for detection of T-Lymphocyte Activation Antigen CD86 (CD86)No significant cross-reactivity or interference between T-Lymphocyte Activation Antigen CD86 (CD86) and analogues was observed.